GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
Executive Summary
A relabeling of GlaxoSmithKline's HIV treatment Ziagen (abacavir sulfate) to recommend pharmacogenomic screening illustrates the potential for FDA's new drug safety tools to encourage the push towards personalized medicine
You may also be interested in...
Autoimmune Drug Reactions To Get Further FDA Research After Ziagen Side Effect Findings
Carriers of the HLAB*57:01 allele who take Ziagen can come down with severe autoimmune reactions due to a mechanism traced by agency researchers.
Tysabri Risk Redux: Additional PML Cases Create REMS Challenge For FDA
The emergence of two new cases of progressive multifocal leukoencephalopathy linked to Biogen Idec/Elan's Tysabri (natalizumab) comes just before the deadline for the firms to submit a formal Risk Evaluation and Mitigation Strategy for the product, and while FDA is still experimenting with how to apply its new REMS authorities
FDA Learns By Doing In Using REMS Powers; Guidance In “Future”
FDA decisions on whether to require a risk evaluation and mitigation strategy for a new drug will continue to be made on a case-by-case basis while the agency gains on-the-job experience in interpreting requirements of the FDA Amendments Act